Reading CYH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CYH free→Reading CYH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CYH free→QuarterlyIQ Insights · CYH
The full factor breakdown (the numbers behind each rank). The overview page shows the same reads in short form; this is the depth.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 0.27x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 40% of the time over the next year (vs 56% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
Not enough signal yet.
Not investment advice. As of 2026-06-12.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.14 → $-0.11 (+20.2% / 30d). 4 raised, 1 cut, 6 covering analysts.
0 upgrades, 0 downgrades / 30d. 22% of analysts rate Buy.
Market and fundamentals agree. Analysts are positioned bullishly on a fundamentally strong name.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.